Investor Presentation - First Six Months of 2021

87 Investor presentation First six months of 2021 Novo NordiskⓇ The medium-term growth is expected to be 6-10% annually driven by securing the base and three future growth enablers Sales increased by 5% from 2013-2018, while medium-term growth is expected to be 6-10% Secure the sales base by leveraging biopharm and portfolio of short-acting and premix insulin ILLUSTRATIVE 5% 6-10% 2013 2014 2015 2016 2017 2018 2025 Future growth drivers Base sales with mature therapy areas Drive additional growth through three future growth enablers Establish basal market leadership Ро Drive GLP-1 market growth D Expand the obesity market

View entire presentation